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Abstract
Behçet disease (BD) is an enigmatic inflammatory disorder with multisystemic complications 
which is endemic in some countries but can be seen in the entire world. Valid diagnostic crite-
ria are available. The pathology is related to a specific perivasculitis with involvement of both 
arteries and veins of all sizes. Minor arterial and cardiac involvement is frequent in BD but 
is usually asymptomatic. In exceptional cases cardiac symptoms may be the 1st manifestation 
of BD. The prevalence of severe cardiac complications (cardio-Behçet) should be < 10%. An 
impressive therapeutic improvement has been achieved by using appropriate catheterization 
techniques, coronary and intra-arterial stents, colchicine, drug-response modifying drugs and 
immunotherapy but, still cardio-Behçet has a poor prognosis. Efforts are undertaken to impro-
ve morbidity and prognosis with the use of newer drugs. An important part of the complications 
in BD are related to the frequent thromboembolic complications and there is high possibility 
that newer oral anticoagulants will be superior to the classical anticoagulants presently used. 
Available biologic agents have already been frequently used and seem to have improved the 
prognosis, but efforts are undertaken to find newer biologic agents with better therapeutic per-
formance and less side-effects.
Summarizing as much as possible the effects of the presently used biotherapy in BD, interferon-a  
is effective against many ocular, genital and perhaps vascular manifestations, but its effec-
tiveness is limited by frequent adverse-effects (even if not dangerous for the cardiovascular 
system). Infliximab is a valid option in the therapy of ocular and cutaneous manifestations but 
it is less convincing in the therapy of vascular manifestations in vascular- and neuro-Behçet; 
furthermore, side-effects, including severe cardiovascular complications, are seen in a minority 
of patients; perhaps worse, infliximab seems to loose efficacy in the long-term therapy, while 
pharmacogenetics and receptor polymorphism may explain the existence of non-responders and 
the occurrence of resistance. Adalimumab might be a promising alternative for infliximab and 
seems to exert a good effect in aneurysmatic and other vascular complications. However, we 
lack long-term studies. Other biologic agents have been used only in few cases and it is too early 
to say if they offer new therapeutic perspectives. (Cardiol J 2014; 21, 2: 105–114)
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Introduction
The terms “Behçet disease”, “vasculo-Behçet”, 
“cardio-Behçet”, “therapy of Behçet disease with 
novel oral anticoagulants” and “immunotherapy in 
Behçet disease” were used for a search through 
MEDLINE, EMBASE, Scopus, and Web of Science. 
Thousands of references were found and we used 
the most important to support our experience with 
the pathology. Our review describes the impact of 
Behçet disease (BD) in frequent (mild) and (rare) 
severe vascular and cardiac complications of BD 
(cardio-Behçet). The therapeutic impact and value 
of novel oral anticoagulants and biologic agents is 
also discussed.
History and epidemiology
BD is a chronic, relapsing, multisystemic di-
sorder, and its historical descriptions can be found 
in the works of Hippocrates and ancient traditional 
Chinese medicine [1]. Adamantiades in 1930 and 
1931 published the pathology of 3 patients with 
relapsing iritis, hypopyon, leg ulcerations and 
thrombophlebitis and stated that this was a new 
nosological entity; however, the pathology became 
really known in 1937 (and since then has been 
called BD) when Behçet also published a paper on 
patients with a triad of recurrent oral and genital 
aphthous ulcerations [2]. BD clusters along the 
ancient Silk Road [3], which extends from eastern 
Asia to the Mediterranean basin, but cases are 
detected in the entire world and not exclusively 
in the migrant population [4].
Diagnosis and classification
The International Study Group (ISG) [5] defi-
ned 5 diagnostic criteria: 2 are mucous membrane 
manifestations, i.e. oral and genital aphthosis, the 
3rd is skin manifestations (pseudofolliculitis and 
erythema nodosum), the 4th is ocular manifesta-
tions (anterior and/or posterior uveitis and retinal 
vasculitis) and the 5th is the pathergy phenomenon. 
In the ISG classification the presence of oral ap-
hthosis is mandatory and 2 of the remaining items 
(genital aphthosis, skin, eye, pathergy phenome-
non) are necessary to acknowledge existence of 
BD. In 2005, 27 multinational experts used large 
numbers of patients and controls with different eth-
nicities and created the International Criteria for 
BD (ICBD) [6]. In the ICBD classification 6 criteria 
are used: 1) mucous (oral and genital) aphthosis, 
2) skin lesions (pseudofolliculitis, erythema no-
dosum), 3) eye lesions (anterior and/or posterior 
uveitis, retinal vasculitis), 4) vascular complica-
tions, 5) vasculitis, and 6) pathergy phenomenon. 
In the ICBD classification genital aphthous lesions 
and eye lesions have bigger diagnostic value than 
the others and give each 2 points; the other 4 items 
get 1 point each. In the ICBD the diagnosis of BD 
is acknowledged when a patient gets ≥ 3 points.
Etiology and pathophysiology
The etiology of BD remains elusive but ethnic 
background, gender-related factors, HLA markers, 
T-lymphocytes dysfunction, circulating immune 
complexes, cytokines, genetically predisposed 
inflammation and hypercoagulation are thought to 
be intimately involved in pathophysiology of BD 
[1, 4]. The underlying pathophysiology of BD is 
a distinctive perivasculitis with involvement of both 
arteries and veins of all sizes [7]. Unlike other sy-
stemic vasculitides and autoimmune diseases, the 
perivasculitis of BD is not associated with anti-Ro, 
antiphospholipid and antineutrophil cytoplasmic 
antibodies [8]. In BD pathological thrombosis 
can be best viewed within the classical Virchow’s 
triad. Vascular complications are: 1) venous and 
2) arterial thrombosis, 3) arterial aneurysm, 
4) combined arterial thrombosis and aneurysm, and 
5) combined venous thrombosis and arterial le-
sions [7]. It is thought that perivascular structures 
are the main target of T-lymphocytes mediated 
immune reactions [9]. The venous and arterial 
wall lesions attract cytokinergic and neutrophilic 
reactions. It is thought [10] that the interleukin-23/ 
/interleukin-17 axis should play a role in inducing 
BD (the interleukin-17 cytokine family consists 
of 6 cytokines, interleukins from 17A to 17F, and 
5 receptors, interleukins from 17RA to 17RE). 
Neutrophils infiltrate the vessels and are activated, 
inducing destructive effects by overproduction of 
superoxide anion radicals and lysosomal enzymes, 
promoting advanced vascular wall destruction with 
aneurysm formation, and in the end causing local 
blood flow abnormalities. Macrophages play an im-
portant pathological role at sites of plaque rupture 
in the thrombosed coronary arteries of patients 
with acute myocardial infarction [11]. It is known 
that apolipoprotein B — containing lipoproteins, 
transforms monocytes into macrophages which in 
turn drive the progression of arterial inflammatory 
lesions [12]. Indeed, monocytes and some mac-
rophages can be detected in the involved arterial 
walls of vascular- and cardio-Behçet patients and 
it is logical to assume that they contribute to the 
complications in these vessels. Disturbed flow ge-
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nerates shear stress and consequently stimulates 
specific mechanosensors located on the surface of 
endothelial cells and consequently pro-atherogenic 
genes are up-regulated and athero-protective ge-
nes are down-regulated. Furthermore, in patients 
with BD, one also finds elevation in some markers 
of endothelial dysfunction (thrombomodulin and 
adhesion molecules) and low-grade inflammation 
(proinflammatory cytokines, C-reactive protein, 
and serum amyloid A), confirming their important 
role in pathophysiology of most immune-media-
ted cardiovascular events in this pathology [13]. 
Finally, in the perivasculitis of BD endothelial 
dysfunction, release of von Willebrand factor, 
platelet activation, enhanced thrombin and fibrin 
generation, antithrombin deficiency and impaired 
fibrinolysis close the pathologic chain of enhanced 
thrombocoagulation [13]. Depending on the organs 
affected by the vascular lesions there is the clinical 
occurrence of a vascular-, neuro-, or cardio-Behçet.
Whatever the complex and still incompletely 
understood mechanisms of the perivasculitis, ve-
nous pathology and thrombotic complications are 
hallmarks of BD, recurrent thrombophlebitis is the 
commonest vascular affection in BD and venous 
involvement is reported in almost one third of 
patients, and arterial involvement in 15% of cases 
[1, 4, 7, 13].
Prevalence of cardio-Behçet
It was recognized that cardiac and arterial 
complications occur and are an important part in 
the complications of BD [1, 4, 7, 14–16]. Cardiac 
involvement in BD is frequent but is usually mild 
and asymptomatic. In countries with endemic BD, 
physicians are familiar with the pathology and are 
inclined to get a cardiological opinion. In referred 
patients electrocardiography, echocardiography 
and, when used, computed tomography or mag-
netic resonance imaging analysis detect subtle 
cardiac changes in about one third of cases (they 
are listed in Table 1). It is, therefore, assumed 
that minor cardiac complications occur in around 
a third of patients with BD [1, 14–17]. As in other 
systemic complications, which are part of the 
Table 1. Asymptomatic cardiac manifestations in Behçet disease, and symptomatic cardiac manifesta-
tions (cardio-Behçet).
A. Detected by electrocardiography
Asymptomatic manifestations Cardio-Behçet
AV-block grade I (or grade II Wenckenbach) AV-block > grade II Mobitz type II
Asymptomatic premature beats Symptomatic premature beats
Asymptomatic brady-/tachycardia Symptomatic brady-tachycardia
Asymptomatic atrial fibrillation Symptomatic atrial fibrillation
Right or left ventricular block
Prolonged QT and abnormal late potentials
Arrhythmias induced by long QT and  
or abnormal late potentials
Myocardial ischemia
Infarction
B. Detected by echocardiography, magnetic resonance imaging and computed tomography
Asymptomatic manifestations Cardio-Behçet
Non occlusive pericarditis Constrictive pericarditis
Mitral prolapse without regurgitation
Ventricular aneurysms and thrombi
Endocarditis with valvular dysfunction
Floppy mitral valve
Major aortic regurgitation
Severe systolic dysfunction
Inter-atrial septal aneurysm
Aneurysmatic enlargement of sinus valsalve  
and ascending aorta
Coronary aneurysms atrial enlargement
Mild systolic or diastolic dysfunction
Minor contractile dysfunction (TDI)
Endocarditis without valvular dysfunction
Endomyocardial fibrosis
Intra-cardiac aneurysms and thrombi
Minor aortic regurgitation
Mitral prolapse with regurgitation
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diagnostic criteria, the cardiac pathology of BD is 
not specific. However, the pathology is conside-
red a complication of BD when biopsies show the 
typical and specific perivasculitis and also when 
these complications are detected in patients with 
BD without an alternative etiology. While minor 
cardiac complications are rarely published, the 
rare cases of cardio-Behçet are interesting and 
often published [1, 17–22], and this situation may 
give the wrong impression that cardio-Behçet is 
not uncommon. In the literature the frequency of 
cardio-Behçet varies between 7% and 46% and this 
large difference shows that the real prevalence is 
unknown. Several reasons contribute to different 
statistics: a) definitions used for cardio-Behçet are 
not standardized; b) important national differences, 
and in countries with endemic experienced physi-
cians detect cardiac complications more often than 
physicians where BD is rare; c) cardio-Behçet is 
really more frequent in some ethnicities [1, 4, 14, 
23]; and 4) referring habits, because if patients are 
sent to hospitals there are mandatory statistics, but 
if they are sent to private cardiologists the cases 
are rarely found in official statistics. Our group has 
a long experience with a small number of patients, 
mostly with migrant origins [1] and centers with 
many cases [18, 22, 23] have seen cardio-Behçet 
in < 10% of referred patients with BD.
Complications and prognosis  
in vasculo-Behçet and cardio-Behçet
The non-cardiac complications of BD were 
described elsewhere [4]. As shown in Table 1, pe-
ricarditis, myocardial involvement (diastolic and/or 
systolic dysfunction), valvular and coronary com-
plications (thrombosis, aneurysms, and rupture), 
predominantly right-sided intra-cardiac thrombi 
and ischemia are the most frequent cardiac ma-
nifestations [1, 15–23]. Good examples of cardio-
-Behçet can be found in our previous paper [1].
Saadoun et al. [23] describe data from 101 
(12.3%) patients with vasculo-Behçet among 
a cohort of 820 patients with BD. Arterial lesions 
included aneurysms (47.3%), occlusions (36.5%), 
stenosis (13.5%), and aortitis (2.7%). Lesions 
mainly involved the aorta (25% of vasculo-Behçet, 
0.03% of patients with BD), femoral arteries 
(22.7% of vasculo-Behçet, 0.028% of patients with 
BD) and pulmonary arteries (0.2% of vasculo-
-Behçet, 0.026% of patients with BD). Patients with 
arterial lesions were more frequently male (91.2% 
vs. 62.4%, respectively, p = 0.017) and had higher 
rates of venous involvement (80.4% vs. 29.8%, re-
spectively, p < 0.001) compared to patients without 
arterial manifestations. In multivariate analysis, 
the presence of venous involvement (odds ratio 
[OR] 0.29, 95% confidence interval [CI] 0.08–1.11) 
and arterial occlusive lesions (OR 0.13, 95% CI 
0.01–1.25) were negatively associated with com-
plete remission. The 20-year survival rate was 
significantly lower in patients with than in those 
without arterial lesions (73% vs. 89%, respec-
tively, p < 0.0001). The use of immunotherapy 
(OR 3.38, 95% CI 0.87–13.23) was associated 
with the occurrence of complete remission and 
improved the prognosis and 39 (38.6%) of 101 
patients with vasculo-Behçet achieved complete 
remission.
In the same paper [23] describes data from 
52 (6%) cases of cardio-Behçet from a cohort of 807 
patients with BD. The duration of disease was 29.3 ± 
± 10.3 years (mean ± SD). Cardiac lesions inclu-
ded pericarditis and thrombosis (19.2%), myocar-
dial infarction (17.3%), endomyocardial fibrosis 
(7.7%) and myocardial aneurysm (1.9%). Patients 
with cardio-Behçet were more frequently male 
(86.5% vs. 64.9%, p < 0.01) and had more arterial 
(42.3% vs. 11.1%, p < 0.01) and venous lesions 
(59.6% vs. 35.8%, p < 0.01) compared to those 
without cardiac manifestations. Factors associated 
with complete remission of cardiac involvement 
were treatment regimens with oral anticoagulants, 
colchicine and immunotherapy. The 5-year survival 
rate was 83.6% and 95.8% (p = 0.03) in patients 
with and without cardiac involvement, respectively. 
After a median follow-up of 3 (range 1.75–4.2) years 
8 cardio-Behçet patients died, and those 3 deaths 
were directly related to cardiac involvement. The 
authors conclude that the prognosis of cardio-
-Behçet patients is poor and improves with oral 
anticoagulation, colchicine and immunotherapy. 
When coronary arteries are affected there is the 
clinical presentation of an acute coronary syndro-
me but, unlike from arteriosclerotic pathologies, 
the coronary pathology occurs in relatively young 
patients without strong association with classical 
cardiovascular risk factors [1, 15].
Affections of inferior vena cava and aorta 
bear the worst prognosis for patients with BD. 
Blood clots can develop in the deep veins of the 
lower extremity and migrate to the right heart 
and pulmonary arteries [17, 21]. In some patients 
with BD, macrophages accumulate in the arteries 
and contribute to arterial rupture, formation of an 
aneurysmatic lesion, and secondary thrombotic 
and ischemic complications. Destruction of elastic 
structures of aorta can result in formation of an-
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eurysms and pseudoaneurysms prone to rupture; 
aneurysms of smaller vessels can also develop, 
sometimes spontaneously [1, 21–23]. The risk of 
aneurysms and pseudoaneurysms is especially 
high in patients undergoing major (angioplasty 
of aorta and its branches, coronary artery bypass 
grafting) or even minor vascular interventions 
(arterial puncture) [19, 20, 22, 24]. Special use of 
catheterization techniques and careful closure of 
the puncture site, combined with appropriate use 
of anticoagulants, reduces the incidence of iatro-
genic aneurysms, but arterial and coronary artery 
aneurysms still occur and remain a major challenge 
in vascular- and cardio-Behçet [19, 24]. 
Our group has already published a paper on 
cardio-Behçet [1]. We add two typical cases. 
Case 1: 39-year-old male patient with migra-
tion origins, without classic cardiovascular risk 
factors. BD was diagnosed 3 years earlier (mucous, 
genital manifestations and pathergy phenomenon) 
and was treated with colchicine and azathioprine. 
Three weeks earlier, the patient noted the occur-
rence of fatigue, dyspnea, chest pain, dry cough, 
dizziness and palpitations. Blood pressure was 
92/60 mm Hg (8 weeks earlier 130/70 mm Hg) and 
NT-proB-type natriuretic peptide > 2000 pg/mL; 
D-dimers and troponin A were normal. As shown 
in Figure 1, the thorax-computed tomography de-
tected a marked left ventricular enlargement and 
the ECG detected tachycardia with frequent and 
repetitive ectopic beats, interpreted as of supra-
ventricular origin with QRS-aberration. The type 
of arrhythmias was confirmed by a 48-h dynamic 
ECG. Coronarography detected insignificant coro-
nary artery lesions and a moderate mitral regur-
gitation; the left ventricular function was reduced 
to 40%, with diffusely reduced contraction but 
without regional dyskinesia. The patient was tre-
ated with b-blockers and diuretics and the cardiac 
function improved within 3 weeks. 
Case 2: 41-year-old male patient without 
migration origins. BD was diagnosed 8 years 
earlier (ocular, genital, vascular manifestations 
and pathergy phenomenon) and was treated with 
colchicine and methotrexate. He also had moderate 
dyslipidemia which was treated with atorvastatin. 
In the previous 48 h, suddenly and several times, 
he experienced typical resting angina pectoris. Tro-
ponin A and D-dimers were strongly positive; ECG 
(Fig. 2) showed ischemic ST-changes from V3 to 
V6. Coronarography detected a significant stenosis 
of the left main coronary artery and, unexpectedly, 
a chest-computed tomography detected an old large 
right pulmonary infarction (a typical complication 
of BD). Under therapy with bivalirudin and ni-
trates the patients was successfully treated with 
percutaneous trasluminal coronary angioplasty 
and implantation of a bare metal stent. The course 
was complicated by an aneurysmatic complication 
at the femoral arterial catheterization site (a typi-
cal complication of BD) which required a special 
occlusion. Under therapy with aspirin, ischemic 
changes, and echocardiography detected a normal 
left ventricular ejection fraction with a small non-
-transmural infarction and hyperkinesia in the left 
anterior wall.
Outcomes and therapy
In the past, lethal outcomes of cardio-Behçet 
were up to 20% [1, 4, 15, 22]. It seems that the 
prognosis of cardio-Behçet improves with the appro-
priate use of colchicine, disease-modifying agents, 
adapted catheterization techniques, endovascular 
stents for aneurysmatic lesions, anticoagulation and 
immunosuppressive therapy [22, 23]. Colchicine 
plays a central role in the therapy of BD [25]. At 
present we are unaware of published data on the 
use of novel oral anticoagulants (i.e. direct factor 
X-inhibitors and thrombin inhibitors) in BD but they 
are being used off-label and seem to offer several 
advantages over heparin and vitamin K antagonists.
The body normally produces low levels of bio-
logical response-modifiers in response to infection 
and disease. Immunotherapy (biotherapy) relies on 
the use of pharmacologically produced biological re-
sponse-modifiers (biologic agents). Several biologic 
agents are used to treat cancer, several autoimmune 
and viral infectious diseases. The therapeutic use 
of biologic agents in cardiology, their heterogeneity 
and cardiovascular safety aspects have been recent 
reviewed [26]. Table 2 summarizes the biologic 
agents presently used in the therapy of BD and 
their mechanism of action. Biotherapy includes 
monoclonal antibodies, interferon, interleukin-2, 
and several types of colony-stimulating factors 
(CSF, GM-colony-stimulating factor and G-colony-
-stimulating factor). Some biologic agents have 
a specific potential for binding to certain receptors, 
an aspect which is related to the genetic basis and 
polymorphism of the receptors; consequently, they 
have a largely variable efficacy in individual patients 
and there is the risk of lack of efficacy (with useless 
high therapeutic costs) or unexpected severe side-
-effects (with high cost of iatrogenic effects); for 
this reason, in Germany, before using some biologic 
agents in oncology, physicians must obtain a phar-
macogenetic tissue test [27, 28].
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Figure 1. Cardio-Behçet, acute congestive cardiac failure; A. Severe left ventricular enlargement; B. Repetitive supra-
ventricular ectopic beats with QRS aberration.
A B
Figure 2. Cardio-Behçet. Acute coronary syndrome with severe occlusion of the left main coronary artery and large 
right pulmonary infarction; A. The ECG shows an ischemic horizontal ST-downsloping in from V3 to V6; B. Corona-
rography shows a significant occlusion of the left main coronary artery; C, D. Chest-computed tomography shows 
a large infarction at the basis of right lung from the surface to the proximity of the heart.
A
B C D
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Controlled data on the use of biotherapy in 
cardio-Behçet are almost unavailable and thus we 
are obliged to use data biologic agents used in other 
complications of BD, and also in these conditions 
more controlled data are needed. However, some 
authors [29, 30] state that there is enough pub-
lished experience to suggest that biotherapy may 
represent an important therapeutic improvement 
for patients with BD who have severe and resistant 
manifestations, or who are intolerant to standard 
immunosuppressive regimens. Considering the 
role of tumor necrosis factor (TNF)-a in triggering 
prothrombotic adhesion molecules, using TNF 
blocking agents in cardio-Behçet could be theoreti-
cally of some interest to reduce venous thrombosis 
relapse. A review [31] reports data from 369 pa-
tients with BD who were treated with biotherapy in 
20 countries. Patients were inadequately controlled 
with, or intolerant to, other immunosuppressive 
regimens, including interferon; 20 patients recei-
ved more than 1 anti-TNF agent, they were mostly 
treated with infliximab, but also with etanercept 
and adalimumab; patients were treated for resi-
stant mucocutaneous, ocular, gastrointestinal, and 
central nervous system involvement (results from 
neuro-Behçet should be useful for the therapy of 
cardio-Behçet because of the similarity in vascular 
lesions). The authors conclude that there is enough 
published experience to suggest that TNF blockade 
represents an important therapeutic advancement 
for patients with severe and resistant, or intolerant, 
to standard immunosuppressive regimens but in 
many cases the use of TNF-antagonists in thrombo-
sis of BD was disappointing especially with regard 
to potential prothrombotic activities and it has also 
found the predisposition to frequent autoantibody 
formation, notably anticardiolipin [32].
Two case-report papers report the use of inflixi-
mab, combined with endovascular intra-aortic sten-
ting, in treating aortitis and 2 cases of pulmonary 
artery aneurysm with intra-cardiac thrombosis, 
1 case with femoral profunda artery aneurysm and 
2 cases with magic syndrome; the therapy induced 
more than a year of complete remission [33, 34]. 
On the other hand, studies on infliximab with a suf-
ficient number of patients with BD deal with ocular 
manifestations [34, 35]. Infliximab has been used 
for 6 years on 50 patients with BD with posterior 
uveitis [34], and it was rapidly effective; mild infu-
sion reactions were recorded in 18% of patients, 
urinary infections in 12%, upper airways infections 
in 16%, and slight liver enzymes in 4% with no 
severe adverse-event requiring infliximab inter-
ruption; lastly, antinuclear antibodies positivity was 
Table 2. Biological agents used in Behçet’s disease (BD).
Drug Class/Action Use in BD
Abatacept Fusion protein composed of the Fc region of the 
immunoglobulin IgG1, fused to the extracellular  
domain of CTLA-4, a molecule capable of binding  
B lymphocytes and prevents the delivery  
of co-stimulatory signal to T cells to fully activate 
them. It also helps to enable down-regulation  
of T-cells by way of T-cell anergy
Neuro-BD
Adalimumab Fully human monoclonal antibody, TNF inhibitor Multiple manifestations
Anakinra Interleukin-1 receptor antagonist Vascular manifestations, neuro-BD
Bevacizumab Humanized monoclonal antibody that inhibits  
vascular endothelial growth factor A
Multiple manifestations
Brodalumab Human monoclonal antibody,  
anti-interleukin-17-receptor
Multiple manifestations
Imatinib Receptor tyrosine kinase inhibitor Multiple manifestations
Infliximab A mouse-human monoclonal chimeric  
antibody to TNF-a
Multiple manifestations
Interferon-a Large class of glycoproteins known as cytokines Multiple manifestations
IL-23p19 antibody Anti-interleukin-23p19-specific antibodies Multiple manifestations
Etanercept A TNF receptor-IgG fusion molecule that  
resembles the TNF-a receptor
Ocular
Rituximab A chimeric monoclonal antibody to CD20 that  
depletes the body of CD20-positive B cell
Ocular
Trastuzumab A humanized murine monoclonal antibody that  
interferes with the HER2/neu receptor
Multiple manifestations
www.cardiologyjournal.org 111
Giuseppe Cocco, Paul Jerie, Cardiac pathology and modern therapeutic approach in Behçet disease
observed in 20% of patients during the whole period 
of follow-up, however, no patients developed signs 
or symptoms of lupus- like syndrome. The other 
paper [35] describes the effects of interferon-a, 
infliximab, etanercept, and rituximab in the treat-
ment of ocular manifestations of patients with BD 
(there are no cases with cardio-Behçet) who respon-
ded poorly to conventional therapies: interferon-a 
was beneficial in the therapy of uveitis and many 
patients enjoyed durable remissions of their ocular 
inflammatory disease even after discontinuation 
of therapy, but side-effects were almost universal 
and some were dangerous. Infliximab was the most 
extensively studied biologic agent: it was rapidly 
effective in many cases of uveitis, though with 
conflicting data concerning the ability to induce 
durable remission after cessation of treatment, and 
adverse-effects were relatively rare but some were 
serious and their list is impressive [37]. A review 
[38] describes the use of infliximab in neuro-Behçet 
and the data might be important for cardio-Behçet: 
the results were not as promising as preliminary 
reports would indicate, and confirm the declining 
therapeutic effect of infliximab in long-term use.
The use of other biologic agents in BD is even 
less documented. Etanercept had little positive 
reports in patients with uveitis [35] but there are 
no data on vasculo-Behçet. Rituximab was effective 
in treating microscopic polyangiitis, Wegener’s 
granulomatosis, and antineutrophil cytoplasmic 
antibodies-associated renal vasculitis [39] and it 
might be effective in vasculo-Behçet. However, the 
use of rituximab in cardio-Behçet may be problema-
tic because the infusion induces many side-effects 
in at least 20% of patients (to reduce their severity 
prior to the infusion of rituximab patients should 
receive acetaminophen, an antihistamine drug and 
sometimes also methylprednisolone) and although 
these symptoms are usually modest, cardiova-
scular adverse-effects of rituximab have included 
myocardial infarction, ventricular fibrillation, and 
cardiogenic shock (as parts of an infusion related 
reaction) and hypotension in 10% of cases [36–39].
In 17 patients with BD, infliximab lost efficacy 
and was replaced with adalimumab (the main manife-
stations requiring switching were the mucocutaneous 
lesions, followed from retinal vasculitis and neuro-
logical involvement); 9 patients showed sustained 
remission and 3 a good response; no side-effects 
were observed [40]. Thus is seems that patients with 
BD who show a scarce response or adverse-events 
to infliximab may be successfully treated with adali-
mumab, but the number of treated patients is small 
and it is premature to say if the efficacy shall last.
Always searching for better therapies, in vitro 
experiments showed that interferon-a could inhibit 
interleukin-17 expression and increased interleu-
kin-10 production by PBMCs and CD4+ T-cells and 
a study reports that the drug was effective in the in 
the therapy of uveitis in patients with BD [41] and 
also in the therapy of gastrointestinal manifesta-
tions of BD [42]. However, interferon-a induces 
many side-effects and there are no published data 
about its use in cardio-Behçet.
The human anti-interleukin-17-receptor mo-
noclonal antibody brodalumab was successfully 
used in the therapy of psoriasis [43] and unpub-
lished data confirm its use in in the therapy of 
severe mucocutaneous manifestation of BD.
Interleukin-23 is a member of the interleu-
kin-12 cytokine family that drives a highly patho-
genic T-cell population involved in the initiation 
of autoimmune diseases; anti-interleukin-23p19-
-specific antibodies inhibited multiple inflammatory 
pathways that are critical for driving autoimmune 
central nervous system inflammation [44]. It is 
likely that anti-interleukin-23 antibodies will be 
used in the therapy of neuro-Behçet. Of course, it 
is unclear if the therapy will be useful in cardio-
-Behçet.
Immunotherapy is considered for the thera-
py of serious manifestations of BD but there are 
problems with its efficacy and safety. The number 
of presently used biologic agents is already large 
and newer drugs are continuously introduced. 
Bevacizumab is an unpleasant candidate because 
it has been found to increase platelet aggregation 
and adhesion to the vascular endothelium [45]. 
Imatinib, another biologic agent, has a proven 
cardiac toxicity and may induce congestive heart 
failure [46]. Searching for a better alternative for 
infliximab, tocilizumab was used to treat severe 
cases of neuro-Behçet [47] but it may be respon-
sible for cardiac toxicity [48].
Interestingly, the way of administration of 
biologic agents may play an important clinical 
role because the subcutaneous use of abatacept 
induced less side-effects than the intravenous 
therapy [49].
Conclusions
BD is an enigmatic inflammatory disorder with 
multisystemic complications which is endemic 
in some countries but can be seen in the entire 
world. Valid diagnostic criteria are available. The 
pathology is related to a specific perivasculitis with 
involvement of both arteries and veins of all sizes. 
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Minor arterial and cardiac involvement is frequent in 
BD but is usually asymptomatic. In exceptional cases 
cardiac symptoms may be the 1st manifestation of 
BD. The prevalence of severe cardiac complications 
(cardio-Behçet) should be < 10%. Impressive the-
rapeutic improvement has been achieved by using 
appropriate catheterization techniques, coronary 
and intra-arterial stents, colchicine, drug-response 
modifying drugs and immunotherapy, but, still, cardio-
-Behçet has a poor prognosis. Efforts are undertaken 
to improve morbidity and prognosis with the use of 
newer drugs. An important part of the complications 
in BD are related to the frequent thromboembolic 
complications and there is a high possibility that 
newer oral anticoagulants will be superior to the 
classical anticoagulants presently used. Available 
biologic agents have already been frequently used and 
seem to have improved the prognosis, but efforts are 
undertaken to find newer biologic agents with better 
therapeutic performance and less side-effects.
Summarizing the effects of the presently used 
biotherapy in BD as much as possible, interferon-a 
is effective against many ocular, genital and, per-
haps, vascular manifestations, but its effectiveness 
is limited by frequent adverse-effects (even if not 
dangerous for the cardiovascular system). Infliximab 
is a valid option in the therapy of ocular and cuta-
neous manifestations but is less convincing in the 
therapy of vascular manifestations in vascular- and 
neuro-Behçet; furthermore, side-effects, including 
severe cardiovascular complications, are seen in 
a minority of patients; perhaps worse, infliximab 
seems to loose efficacy in long-term therapy, while 
pharmacogenetics and receptor polymorphism may 
explain the existence of non-responders and the 
occurrence of resistance. Adalimumab might be 
a promising alternative for infliximab and seems to 
exert a good effect in aneurysmatic and other va-
scular complications. However, we lack long-term 
studies. Other biologic agents have been used only 
in few cases and it is too early to say if they offer 
new therapeutic perspectives.
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